High-Dose Brolucizumab for Refractory Neovascular Age-Related Macular Degeneration Resistant to Standard-Dose Brolucizumab.

Jinsoo KimMin Seon ParkBum-Joo ChoSoonil Kwon

Published in: Ophthalmology and therapy (2024)

High-dose brolucizumab was effective in patients who did not respond to standard-dose brolucizumab after switching from previous anti-VEGF agents. Increasing the dosage could offer sustained disease control and reduce the treatment burden for patients with refractory AMD.

Keyphrases

age related macular degeneration
high dose
low dose
stem cell transplantation
vascular endothelial growth factor
endothelial cells
risk factors
combination therapy
smoking cessation